ArticleBMC infectious diseases2025
Plasma and CSF pharmacokinetic characteristics of second-line anti-tuberculosis drugs in a patient with multidrug-resistant tuberculous meningitis.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Management ofOpen forum infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe treatment of multidrug-resistant tuberculous meningitis (MDR-TBM) presents significant challenges, as the ability of different anti-tuberculosis (anti-TB) drugs to penetrate the blood-brain barrier varies greatly. The pharmacokinetic characteristics of second-line anti-TB drugs including bedaquiline, cycloserine, moxifloxacin and contezolid remains unclear, particularly in cerebrospinal fluid (CSF). CASE PRESENTATION: We report a case of a 30-year-old female who was diagnosed with MDR-TBM. Therapeutic drug monitoring (TDM) was used to determine whether each anti-TB drug’s peak concentration reached the effective range, and concentrations of each anti-TB drug in plasma and CSF of the patient after 5, 7, 9 and 12 h of medication was detected, the CSF/plasma concentration ratio of each anti-TB drug was also analyzed.
conclusionsTDM plays an important role in clinical individualized medication adjustment. Cycloserine, pyrazinamide, contezolid and moxifloxacin may have a high CSF permeability. This study provided valuable reference for the clinical management of MDR-TBM by measuring the plasma and CSF concentrations of anti-TB drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.